Immuron reveals anti-COVID potential, raises $28 million
Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.
https://www.aumanufacturing.com.au/immuron-reveals-anti-covid-potential-raises-28-million
Filter by Year:
- Immuron (ASX:IMC) enters research agreement with Monash University
- Could Immuron’s (ASX:IMC) traveller’s diarrhoea treatment be used to fight COVID-19?
- Immuron reveals anti-COVID potential, raises $28 million
- Walter Reid Army Institute of Research 2019 Year in Review
- Immuron partnering with Walter Reid Army Institute of Research to test Travelan against Shigella, ETEC, Vibrio cholerae and Campylobacter jejuni isolates (2020, WRAIR's Investigator's Dispatch)
- Diarrhea: A major health issue for Americans travelling abroad
This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.
